FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208863945> ?p ?o ?g. }

• W3208863945 endingPage "S24" @default.
• W3208863945 startingPage "S24" @default.
• W3208863945 abstract "Purpose/Objective(s)Patients 70 years old or younger with good performance status with glioblastoma often are treated with radiotherapy (RT) over 6 weeks with concurrent and adjuvant temozolomide. Whether short-course hypofractionated RT using the same total dose over a shorter time has similar clinical efficacy without increased toxicity is presently not known. Primary objective was to compare outcomes between conventional and short-course RT regimens.Materials/MethodsWe conducted a randomized noninferiority trial for patients aged 18-70 years with histologically confirmed, newly diagnosed glioblastoma and ECOG 0-2. Patients were randomized in a 1:1 ratio, stratified by extent of surgical resection, to conventional RT of 60 Gy in 30 fractions over 6 weeks or short-course RT of 60 Gy in 20 fractions over 4 weeks, with concomitant and maintenance temozolomide in both arms. Primary endpoint was overall survival defined as time from randomization until death. Secondary endpoints included acute and late toxicity graded according to NCI CTCAE version 4.0, and patient-reported quality of life assessed by EORTC QLQ-C30 and QLQ-BN20 questionnaires. Survival outcomes were analyzed by intention to treat. Noninferiority margin was 14.5% (hazard ratio, < 1.57).ResultsOne hundred thirty-three patients were randomized to short-course arm (n = 68) or conventional arm (n = 65). Median age was 58 years (range 24-70); 69% male; 91% had ECOG 0-1; 88% had resection. In prospective molecular analysis of suitable specimens, IDH1 mutation was seen in 13/131 patients (9.9%) and MGMT promotor methylation in 68/126 patients (54.0%). Age (< 60 vs. ≥60 years), ECOG (0-1 vs. 2), extent of resection (resection vs. biopsy), IDH1 status (wildtype vs. mutated), MGMT status (methylated vs. unmethylated), and extent of disease (unifocal vs. multifocal) were not different between two arms. Median overall survival was 14.4 months (95% CI 12.7 – 16.1 months) in the short-course arm; 11.0 months (95% CI 9.2 – 12.8 months) in the conventional arm (HR 0.94, 95% CI 0.64 – 1.38, P-value for superiority = 0.751, P-value for non-inferiority < 0.01). In 97 patients without multifocal disease, median overall survival was 15.3 months (95% CI 13.0 - 17.7 months) in the short-course arm; 11.8 months (95% CI 9.4 -14.2 months) in the conventional arm (HR 0.95, 95% CI 0.62 – 1.46, P = 0.816). With median follow-up time of 18.7 months, no significant differences were detected between arms for any grade ≥2 toxicity. No patients had reoperation for radionecrosis in the short-course arm. In the conventional arm, one patient had reoperation for radionecrosis. Quality of life between both arms at the end of RT, and at 12 weeks and 16 weeks post-RT was not different.ConclusionThe short-course RT regimen used in this trial was not inferior to conventional RT and was not associated with increased toxicity or reduced quality of life. Short-course RT is more convenient for patients and may be recommended as a treatment option for patients 70 years old or younger with newly diagnosed glioblastoma. Patients 70 years old or younger with good performance status with glioblastoma often are treated with radiotherapy (RT) over 6 weeks with concurrent and adjuvant temozolomide. Whether short-course hypofractionated RT using the same total dose over a shorter time has similar clinical efficacy without increased toxicity is presently not known. Primary objective was to compare outcomes between conventional and short-course RT regimens. We conducted a randomized noninferiority trial for patients aged 18-70 years with histologically confirmed, newly diagnosed glioblastoma and ECOG 0-2. Patients were randomized in a 1:1 ratio, stratified by extent of surgical resection, to conventional RT of 60 Gy in 30 fractions over 6 weeks or short-course RT of 60 Gy in 20 fractions over 4 weeks, with concomitant and maintenance temozolomide in both arms. Primary endpoint was overall survival defined as time from randomization until death. Secondary endpoints included acute and late toxicity graded according to NCI CTCAE version 4.0, and patient-reported quality of life assessed by EORTC QLQ-C30 and QLQ-BN20 questionnaires. Survival outcomes were analyzed by intention to treat. Noninferiority margin was 14.5% (hazard ratio, < 1.57). One hundred thirty-three patients were randomized to short-course arm (n = 68) or conventional arm (n = 65). Median age was 58 years (range 24-70); 69% male; 91% had ECOG 0-1; 88% had resection. In prospective molecular analysis of suitable specimens, IDH1 mutation was seen in 13/131 patients (9.9%) and MGMT promotor methylation in 68/126 patients (54.0%). Age (< 60 vs. ≥60 years), ECOG (0-1 vs. 2), extent of resection (resection vs. biopsy), IDH1 status (wildtype vs. mutated), MGMT status (methylated vs. unmethylated), and extent of disease (unifocal vs. multifocal) were not different between two arms. Median overall survival was 14.4 months (95% CI 12.7 – 16.1 months) in the short-course arm; 11.0 months (95% CI 9.2 – 12.8 months) in the conventional arm (HR 0.94, 95% CI 0.64 – 1.38, P-value for superiority = 0.751, P-value for non-inferiority < 0.01). In 97 patients without multifocal disease, median overall survival was 15.3 months (95% CI 13.0 - 17.7 months) in the short-course arm; 11.8 months (95% CI 9.4 -14.2 months) in the conventional arm (HR 0.95, 95% CI 0.62 – 1.46, P = 0.816). With median follow-up time of 18.7 months, no significant differences were detected between arms for any grade ≥2 toxicity. No patients had reoperation for radionecrosis in the short-course arm. In the conventional arm, one patient had reoperation for radionecrosis. Quality of life between both arms at the end of RT, and at 12 weeks and 16 weeks post-RT was not different. The short-course RT regimen used in this trial was not inferior to conventional RT and was not associated with increased toxicity or reduced quality of life. Short-course RT is more convenient for patients and may be recommended as a treatment option for patients 70 years old or younger with newly diagnosed glioblastoma." @default.
• W3208863945 created "2021-11-08" @default.
• W3208863945 creator A5000780503 @default.
• W3208863945 creator A5006236988 @default.
• W3208863945 creator A5012339281 @default.
• W3208863945 creator A5037247530 @default.
• W3208863945 creator A5038063803 @default.
• W3208863945 creator A5057587870 @default.
• W3208863945 creator A5066482001 @default.
• W3208863945 creator A5069016257 @default.
• W3208863945 creator A5091878718 @default.
• W3208863945 date "2021-11-01" @default.
• W3208863945 modified "2023-09-26" @default.
• W3208863945 title "A Randomized Trial of Short-Course Versus Conventional Radiotherapy With Concomitant and Adjuvant Temozolomide in Patients 18 to 70 Years of Age With Glioblastoma" @default.
• W3208863945 doi "https://doi.org/10.1016/j.ijrobp.2021.07.083" @default.
• W3208863945 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34700516" @default.
• W3208863945 hasPublicationYear "2021" @default.
• W3208863945 type Work @default.
• W3208863945 sameAs 3208863945 @default.
• W3208863945 citedByCount "2" @default.
• W3208863945 countsByYear W32088639452022 @default.
• W3208863945 crossrefType "journal-article" @default.
• W3208863945 hasAuthorship W3208863945A5000780503 @default.
• W3208863945 hasAuthorship W3208863945A5006236988 @default.
• W3208863945 hasAuthorship W3208863945A5012339281 @default.
• W3208863945 hasAuthorship W3208863945A5037247530 @default.
• W3208863945 hasAuthorship W3208863945A5038063803 @default.
• W3208863945 hasAuthorship W3208863945A5057587870 @default.
• W3208863945 hasAuthorship W3208863945A5066482001 @default.
• W3208863945 hasAuthorship W3208863945A5069016257 @default.
• W3208863945 hasAuthorship W3208863945A5091878718 @default.
• W3208863945 hasBestOaLocation W32088639451 @default.
• W3208863945 hasConcept C116263406 @default.
• W3208863945 hasConcept C126322002 @default.
• W3208863945 hasConcept C141071460 @default.
• W3208863945 hasConcept C143998085 @default.
• W3208863945 hasConcept C168563851 @default.
• W3208863945 hasConcept C203092338 @default.
• W3208863945 hasConcept C204243189 @default.
• W3208863945 hasConcept C207103383 @default.
• W3208863945 hasConcept C2776694085 @default.
• W3208863945 hasConcept C2776907518 @default.
• W3208863945 hasConcept C2777389519 @default.
• W3208863945 hasConcept C2779384505 @default.
• W3208863945 hasConcept C29730261 @default.
• W3208863945 hasConcept C44249647 @default.
• W3208863945 hasConcept C509974204 @default.
• W3208863945 hasConcept C71924100 @default.
• W3208863945 hasConceptScore W3208863945C116263406 @default.
• W3208863945 hasConceptScore W3208863945C126322002 @default.
• W3208863945 hasConceptScore W3208863945C141071460 @default.
• W3208863945 hasConceptScore W3208863945C143998085 @default.
• W3208863945 hasConceptScore W3208863945C168563851 @default.
• W3208863945 hasConceptScore W3208863945C203092338 @default.
• W3208863945 hasConceptScore W3208863945C204243189 @default.
• W3208863945 hasConceptScore W3208863945C207103383 @default.
• W3208863945 hasConceptScore W3208863945C2776694085 @default.
• W3208863945 hasConceptScore W3208863945C2776907518 @default.
• W3208863945 hasConceptScore W3208863945C2777389519 @default.
• W3208863945 hasConceptScore W3208863945C2779384505 @default.
• W3208863945 hasConceptScore W3208863945C29730261 @default.
• W3208863945 hasConceptScore W3208863945C44249647 @default.
• W3208863945 hasConceptScore W3208863945C509974204 @default.
• W3208863945 hasConceptScore W3208863945C71924100 @default.
• W3208863945 hasIssue "3" @default.
• W3208863945 hasLocation W32088639451 @default.
• W3208863945 hasLocation W32088639452 @default.
• W3208863945 hasOpenAccess W3208863945 @default.
• W3208863945 hasPrimaryLocation W32088639451 @default.
• W3208863945 hasRelatedWork W1484022485 @default.
• W3208863945 hasRelatedWork W2081094155 @default.
• W3208863945 hasRelatedWork W2244282381 @default.
• W3208863945 hasRelatedWork W2361498120 @default.
• W3208863945 hasRelatedWork W3028668968 @default.
• W3208863945 hasRelatedWork W3208863945 @default.
• W3208863945 hasRelatedWork W4212846356 @default.
• W3208863945 hasRelatedWork W4251004304 @default.
• W3208863945 hasRelatedWork W4294682775 @default.
• W3208863945 hasRelatedWork W4311299745 @default.
• W3208863945 hasVolume "111" @default.
• W3208863945 isParatext "false" @default.
• W3208863945 isRetracted "false" @default.
• W3208863945 magId "3208863945" @default.
• W3208863945 workType "article" @default.